• Please log in or register to access this feature.

Viral Hepatitis

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial†‡

  1. Sandra De Meyer1,§,*,
  2. Inge Dierynck1,
  3. Anne Ghys1,
  4. Maria Beumont1,
  5. Bjorn Daems1,
  6. Ben Van Baelen1,
  7. James C. Sullivan2,
  8. Douglas J. Bartels2,
  9. Tara L. Kieffer2,
  10. Stefan Zeuzem3,
  11. Gaston Picchio4

Article first published online: 4 DEC 2012

DOI: 10.1002/hep.25962

Issue

Hepatology

Hepatology

Volume 56, Issue 6, pages 2106–2115, December 2012

Additional Information

How to Cite

De Meyer, S., Dierynck, I., Ghys, A., Beumont, M., Daems, B., Van Baelen, B., Sullivan, J. C., Bartels, D. J., Kieffer, T. L., Zeuzem, S. and Picchio, G. (2012), Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial. Hepatology, 56: 2106–2115. doi: 10.1002/hep.25962

Author Information

  1. 1

    Janssen Infectious Diseases BVBA, Beerse, Belgium

  2. 2

    Vertex Pharmaceuticals Inc., Cambridge, MA

  3. 3

    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany

  4. 4

    Janssen Research and Development, Titusville, NJ

  1. §

    fax: +32 14 641 928

*Janssen Infectious Diseases BVBA, Beerse, Belgium

  1. †

    Potential conflict of interest: Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, Bjorn Daems, and Ben Van Baelen are full-time employees of Janssen Infectious Diseases BVBA. James C. Sullivan, Douglas J Bartels, and Tara L. Kieffer are full-time employees of Vertex Pharmaceuticals. Stefan Zeuzem has been a consultant for Abbott, Anadys, Achillion, Bristol-Myers Squibb, Gilead, Novartis, Merck, Pfizer, Pharmasset, Roche, Vertex Pharmaceuticals, Tibotec Inc., Santaris, and iTherX. Gaston Picchio is a full-time employee of Janssen Research and Development.

  2. ‡

    The clinical trial was sponsored by Janssen Pharmaceuticals and Vertex Pharmaceuticals. Medical writing support and general editorial assistance for this article was provided by Ryan Woodrow and Joanne Williams (Medical Writers, Gardiner-Caldwell Communications, Macclesfield, UK) and funded by Janssen Pharmaceuticals.

  3. §

    fax: +32 14 641 928

Publication History

  1. Issue published online: 4 DEC 2012
  2. Article first published online: 4 DEC 2012
  3. Accepted manuscript online: 16 JUL 2012 05:13PM EST
  4. Manuscript Accepted: 18 JUN 2012
  5. Manuscript Received: 28 FEB 2012

Funded by

  • Janssen Pharmaceuticals and Vertex Pharmaceuticals
  • general editorial assistance
  • Medical Writers, Gardiner-Caldwell Communications, Macclesfield, UK)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (707K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (707K)